A phase 3 study assessed pozdeutinurad compared with placebo in patients with gout who were inadequate responders to prior therapies.

For physicians who have left clinical practice, hassle factor and too stressful are prime motivations for departure, according to a study published online May ...

Retatrutide demonstrated substantial dose-dependent improvements in waist circumference and crucial cardiovascular risk factors, including non-HDL-C, triglycerides, systolic blood pressure, and ...

Use of calcium, vitamin D, or combined supplementation has little to no effect on the prevention of fractures and falls in adults, according to a review publi ...

Leucovorin prescription rates increased steadily through August 2025, then increased sharply through November 2025. (HealthDay News) — For pediatric patients with autism spectrum disorder (ASD), ...

Vosoritide met its primary endpoint by significantly increasing annualized growth velocity (+2.33cm/yr) in children with hypochondroplasia, while maintaining a safety profile consistent with its use ...

In the FINE-ONE trial, finerenone met its primary endpoint by significantly reducing the urinary albumin-to-creatinine ratio by 25% compared with placebo over 6 months in adults with T1D and CKD. The ...

Investigators conducted a retrospective cohort study to assess the real-world impact of shifting from hormone replacement to natural cycle frozen embryo transfer.

Patients have reportedly experienced classic Ebola disease symptoms like fever, headache, vomiting, severe weakness, abdominal pain, nosebleeds and vomiting blood, the CDC said.

Among patients with obesity, GLP-1 RAs were associated with a lower hazard of all-cause mortality and recurrence-free survival over a 10-year follow-up period. (HealthDay News) — Glucagon-like peptide ...

Two interchangeable golimumab biosimilars were approved for the treatment of rheumatoid arthritis and ulcerative colitis.

Supported by phase 3 trial data showing significant SARA score improvements, levacetylleucine is on track to potentially become the first approved therapy for A-T.